18 January 2024 - On-going RAMP 203 trial assessing a more complete vertical blockade with RAF/MEK and KRAS G12C inhibition along ...
18 January 2024 - Since July 2023, there has been one in Germany for patients who suffer from acute myeloid leukaemia ...
17 January 2024 - We aimed to identify and quantify factors associated with launch prices and post-launch price changes of ...
17 January 2024 - NICE has published evidence-based recommendations on the use of olaparib (Lynparza) in combination with bevacizumab (Avastin) ...
16 January 2024 - Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq ...
16 January 2024 - Fast track designation follows positive Phase 1 data presented at the American Society of Hematology that supports ...
11 January 2024 - Ono Pharmaceutical Korea said Thursday that Braftovi (encorafenib), a targeted therapy for BRAF V600E mutated metastatic ...
10 January 2024 - NICE has published evidence-based recommendations on the use of durvalumab (Imfinzi) in combination with cisplatin and ...
12 January 2024 - RemeGen announced recently that its independently developed mesothelin targeting antibody drug conjugate RC88 has been granted fast ...
9 January 2024 - Shorla Oncology announced today that the US FDA has accepted for review the company’s new drug application ...
15 January 2024 - On 12 January 2024, the FDA approved pembrolizumab (Keytruda) with chemoradiotherapy for patients with FIGO 2014 stage ...
10 January 2024 - Mirati Therapeutics today announced that the European Commission granted conditional marketing authorisation for Krazati (adagrasib) as ...
9 January 2024 - Submission based on positive results from global Phase 3 study demonstrating overall survival benefit of TIVDAK ...
8 January 2024 - Talzenna is the first and only PARP inhibitor approved in combination with standard of care Xtandi ...
9 January 2024 - Sellas Life Sciences Group today announced that the US FDA has granted fast track designation to SLS009 ...